Treatment of relapsed or refractory chronic lymphocytic leukemia.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Cancer Control: Journal of the Moffitt Cancer Cente

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/107327481201900105PMID 22143061
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia

  2011cited by this paper
• The novel antisense Bcl-2 inhibitor SPC2996 causes rapid leukemic cell clearance and immune activation in chronic lymphocytic leukemia

  2011cited by this paper
• Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categories.

  2010cited by this paper
• Superior Efficacy of the Novel Type II, Glycoengineered CD20 Antibody GA101vs. the Type I CD20 Antibodies Rituximab and Ofatumumab

  2010cited by this paper
• Response, Progression-Free Survival, and Overall Survival of Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Flavopiridol: Impact of Poor Risk Cytogenetic Abnormalities

  2010cited by this paper
• The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

  2010cited by this paper
• Spleen Tyrosine Kinase (Syk) Inhibitors Block B Cell Receptor Signaling and Survival In Chronic Lymphocytic Leukemia

  2010cited by this paper
• A Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, In Combination with Rituximab and/or Bendamustine In Patients with Relapsed or Refractory B-Cell Malignancies.

  2010cited by this paper
• Update on the Phase I Study of the Cyclin Dependent Kinase Inhibitor Dinaciclib (SCH 727965) In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity and Feasibility of Long-Term Administration

  2010cited by this paper
• Fludarabine, Cyclophosphamide, and Alemtuzumab (FCC) In Relapsed/Refractory Patients with B-Cell Chronic Lymphocytic Leukemia (CLL): Final Report of the Italian Study

  2010cited by this paper
• Interim Analysis of EFC6663, a Multicenter Phase 2 Study of Alvocidib (flavopiridol), Demonstrates Clinical Responses Among Patients with Fludarabine Refractory CLL

  2010cited by this paper
• Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.

  2010cited by this paper
• Targeting kinases in CML CLL.

  2010cited by this paper
• The BENDALEM CLL 6 AGMT Study – Bendamustine Combined with Alemtuzumab In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): Results of a Planned Interim Analysis

  2010cited by this paper
• Response to Dasatinib In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Correlates with p-Lyn and p-Syk

  2010cited by this paper
• A Phase I Study of Escalated Dose Subcutaneous Alemtuzumab Given Weekly with Rituximab In Relapsed CLL/SLL.

  2010cited by this paper
• Ofatumumab and High-Dose Methylprednisolone Is An Effective Salvage Treatment for Heavily Pretreated, Unfit or Refractory Patients with Chronic Lymphocytic Leukemia: Single Institution Experience

  2010cited by this paper
• The clinical application of monoclonal antibodies in chronic lymphocytic leukemia.

  2010cited by this paper
• The Bruton's Tyrosine Kinase Inhibitor, PCI-32765, Is Well Tolerated and Demonstrates Promising Clinical Activity In Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): An Update on Ongoing Phase 1 Studies

  2010cited by this paper
• Phase II Study of Dasatinib In Patients with Relapsed Chronic Lymphocytic Leukemia.

  2010cited by this paper
• The Btk Inhibitor, PCI-32765, Induces Durable Responses with Minimal Toxicity In Patients with Relapsed/Refractory B-Cell Malignancies: Results From a Phase I Study

  2010cited by this paper
• Final Analysis From the International Trial of Single-Agent Ofatumumab In Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia

  2010cited by this paper
• CNS Disease In Younger Patients (

  2010cited by this paper
• Navitoclax (ABT-263) Plus Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR): A Phase 1 Study In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

  2010cited by this paper
• Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.

  2010cited by this paper
• Results of a Phase I-II Clinical Trial of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab (OFAR) Combination Therapy In Patients with Aggressive, Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Richter Syndrome (RS)

  2010cited by this paper
• Monoclonal antibody therapy of chronic lymphocytic leukaemia.

  2010cited by this paper
• Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence

  2010cited by this paper
• Dinaciclib (SCH727965) Is a Novel Cyclin Dependent Kinase Inhibitor That Promotes Selective Apoptosis In CLL Cells and Abrogates the Protective Effects of Microenvironment Cytokines

  2010cited by this paper
• Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.

  2010cited by this paper
• Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.

  2010cited by this paper
• Understanding and managing ultra high-risk chronic lymphocytic leukemia.

  2010cited by this paper
• Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia

  2009cited by this paper
• RITUXIMAB IN COMBINATION WITH HIGH DOSE METHYLPREDNISOLONE FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA

  2009cited by this paper
• Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study

  2009cited by this paper
• Treatment of fludarabine‐refractory chronic lymphocytic leukemia

  2009cited by this paper
• Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced‐stage, relapsed chronic lymphocytic leukaemia

  2009cited by this paper
• Phase I Study of RO5072759 (GA101) in Relapsed/Refractory Chronic Lymphocytic Leukemia.

  2009cited by this paper
• Improved Progression-Free Survival (PFS) of Alemtuzumab (Campath®, MabCampath®) Plus Fludarabine (Fludara®) Versus Fludarabine Alone as Second-Line Treatment of Patients with B-Cell Chronic Lymphocytic Leukemia: Preliminary Results From a Phase III Randomized Trial.

  2009cited by this paper
• Role of bendamustine in the treatment of chronic lymphocytic leukemia

  2009cited by this paper
• Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia.

  2009cited by this paper
• AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance.

  2009cited by this paper
• State-of-the-art treatment of chronic lymphocytic leukemia.

  2009cited by this paper
• Bendamustine/mitoxantrone/rituximab: a short remission induction chemoimmunotherapy for elderly patients with relapsed or refractory chronic lymphocytic leukemia

  2009cited by this paper
• 5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen.

  2009cited by this paper
• Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.

  2009cited by this paper
• Flavopiridol in chronic lymphocytic leukemia: a concise review.

  2009cited by this paper
• Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia

  2009cited by this paper
• Crystal Structure Analysis Reveals That the Novel Type II Anti-CD20 Antibody GA101 Interacts with a Similar Epitope as Rituximab and Ocrelizumab but in a Fundamentally Different Way.

  2009cited by this paper
• Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia.

  2009cited by this paper
• B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406.

  2009cited by this paper
• Chemoimmunotherapy with Cyclophosphomide, Fludarabine, Alemtuzumab and Rituximab (CFAR) Is Effective in Relapsed Patients with Chronic Lymphocytic Leukemia (CLL).

  2009cited by this paper
• Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease.

  2009cited by this paper
• A Phase 1 Trial of SNS-032, a Potent and Specific CDK 2, 7 and 9 Inhibitor, in Chronic Lymphocytic Leukemia and Multiple Myeloma

  2008cited by this paper
• Bendamustine (Treanda) Displays a Distinct Pattern of Cytotoxicity and Unique Mechanistic Features Compared with Other Alkylating Agents

  2008cited by this paper
• Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.

  2008cited by this paper
• A Phase I/II Study of RO5072759 (GA101) in Patients with Relapsed/Refractory CD20+ Malignant Disease

  2008cited by this paper
• A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia

  2008cited by this paper
• Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study.

  2008cited by this paper
• Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.

  2008cited by this paper
• An Ongoing Phase 1 Study of ABT-263; Pharmacokinetics, Safety and Anti-Tumor Activity in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

  2008cited by this paper
• Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells.

  2008cited by this paper
• Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia

  2008cited by this paper
• Valproic Acid Sensitizes Chronic Lymphocytic Leukemia Cells to Apoptosis and Restores the Balance Between Pro- and Antiapoptotic Proteins

  2008cited by this paper
• Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma.

  2008cited by this paper
• Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.

  2007cited by this paper
• Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia.

  2007cited by this paper
• Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia

  2007cited by this paper
• The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy

  2007cited by this paper
• A Phase II, Open Label Study of AT-101 in Combination with Rituximab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. Evaluation of Two Dose Regimens.

  2007cited by this paper
• Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical.

  2007cited by this paper
• Phase 1 Study of Lumiliximab with Detailed Pharmacokinetic and Pharmacodynamic Measurements in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

  2007cited by this paper
• Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features

  2007cited by this paper
• Bendamustine in Combination with Rituximab (BR) for Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): A Multicentre Phase II Trial of the German CLL Study Group (GCLLSG)

  2007cited by this paper
• Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy

  2006cited by this paper
• The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD201

  2006cited by this paper
• Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects

  2006cited by this paper
• Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia.

  2006cited by this paper
• Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism

  2006cited by this paper
• ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia.

  2005cited by this paper
• Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival.

  2005cited by this paper
• AT 101, an Inhibitor of Bcl-2 Family Members Is Cytotoxic to a Heterogeneous Group of CLL Samples and Synergistic with Rituximab.

  2005cited by this paper
• SPC2996 - A New Bcl-2 Inhibitor for the Treatment of CLL.

  2005cited by this paper
• Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial.

  2005cited by this paper
• Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia.

  2005cited by this paper
• Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group.

  2005cited by this paper
• Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia.

  2005cited by this paper
• Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma.

  2005cited by this paper
• A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia.

  2004cited by this paper
• Bendamustine/Mitoxantrone/Rituximab (BMR): A Very Effective, Well Tolerated Outpatient Chemoimmunotherapy for Relapsed and Refractory CD20-positive Indolent Malignancies. Final Results of a Pilot Study

  2004cited by this paper
• Bendamustine Plus Mitoxantrone—A New Effective Treatment for Advanced Chronic Lymphocytic Leukaemia: Results of a Phase I/II Study

  2004cited by this paper
• Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions.

  2004cited by this paper
• Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-X(L).

  2004cited by this paper
• Fludarabine, Cyclophosphamide and Mitoxantrone in Relapsed or Refractory Chronic Lymphocytic Leukemia and Low Grade Non-Hodgkin's Lymphoma

  2004cited by this paper
• A Pilot Trial of Rituximab and Alemtuzumab Combination Therapy in Patients with Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL)

  2004cited by this paper
• Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia

  2004cited by this paper
• Rational Design and Real Time, In-Cell Detection of the Proapoptotic Activity of a Novel Compound Targeting Bcl-XL

  2004cited by this paper
• Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas.

  2004cited by this paper
• Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia.

  2003cited by this paper
• Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein.

  2003cited by this paper

• The Role of Daily Activity in Risk and Survival Outcomes for Chronic Lymphocytic Leukemia Patients: Baseline Insights from the ADRENALINE Pilot Study

  2025cites this paper
• Targeting chronic lymphocytic leukemia with B‐cell activating factor receptor CAR T cells

  2024cites this paper
• Epidemiological Features of Acute Myeloid Leukemia in Five Regions of the Republic of Kazakhstan: Population Study

  2022cites this paper
• Silencing Notch-1 enhances fludarabine chemosensitivity in chronic lymphocytic leukemia

  2019cites this paper
• Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial

  2019cites this paper
• Ibrutinib and fungus: an invasive concern.

  2018cites this paper
• Chronic lymphocytic leukaemia: A guide for practice nurses

  2018cites this paper
• Ibrutinib in the Treatment of Relapsed Chronic Lymphocytic Leukemia

  2018cites this paper
• Bulletin : Hematopoietic Cell Transplantation for Non-Hodgkin ' s Lymphoma

  2018cites this paper
• Chimeric antigen receptor T cell therapy for non-Hodgkin lymphoma.

  2018cites this paper
• Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study

  2017cites this paper
• Biological Drugs in Guillain-Barré Syndrome: An Update

  2017influential citation
• Time to Second‐line Treatment and Subsequent Relative Survival in Older Patients With Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

  2017cites this paper
• Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia

  2017cites this paper
• Genomic and transcriptomic sequencing in chronic lymphocytic leukemia

  2016cites this paper
• Stable isotope-labelled intravenous microdose for absolute bioavailability and effect of grapefruit juice on ibrutinib in healthy adults.

  2016cites this paper
• Idelalisib- a PI3Kδ targeting agent for B-cell malignancies

  2016cites this paper
• Lenalidomide Induced Graft Versus Leukemia in a Cll Patient Who Relapsed After Allogeneic Stem Cell Transplantion

  2016cites this paper
• Chronic lymphocytic leukemia: a clinical review including Korean cohorts

  2016cites this paper
• Recent Developments in Cellular Immunotherapy for HSCT-Associated Complications

  2016cites this paper
• Subcutaneous injections of low doses of humanized anti-CD20 veltuzumab: a phase I study in chronic lymphocytic leukemia*

  2016cites this paper
• The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia.

  2015cites this paper
• A Novel Natural Product, KL-21, Inhibits Proliferation and Induces Apoptosis in Chronic Lymphocytic Leukemia Cells

  2015cites this paper
• Ellagic acid, a polyphenolic compound, selectively induces ROS-mediated apoptosis in cancerous B-lymphocytes of CLL patients by directly targeting mitochondria

  2015cites this paper
• Salvage outcomes in patients with first relapse after fludarabine, cyclophosphamide, and rituximab for chronic lymphocytic leukemia: The French intergroup experience

  2015cites this paper
• Indole-3-Carbinol Synergizes with and Restores Fludarabine Sensitivity in Chronic Lymphocytic Leukemia Cells Irrespective of p53 Activity and Treatment Resistances

  2015cites this paper
• Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia

  2015cites this paper
• Strategies targeting apoptosis proteins to improve therapy of chronic lymphocytic leukemia.

  2015cites this paper
• Allogeneic hematopoietic stem cell transplantation for poor-risk CLL: dissecting immune-modulating strategies for disease eradication and treatment of relapse

  2015cites this paper
• Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway

  2015cites this paper
• Erfolgreiche Behandlung eines therapierefraktären Guillain-Barré-Syndroms mit Alemtuzumab bei einem Patienten mit chronischer lymphatischer Leukämie

  2015cites this paper
• Pharmacoeconomic analysis of the use of gazyva (obinutuzumab) for the treatment of chronic lymphocytic leukemia in the Russian Federation

  2015cites this paper
• Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

  2015cites this paper
• Paradigm shifts in the management of poor-risk chronic lymphocytic leukemia

  2015cites this paper
• and high-dose methylprednisolone for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia.

  2014cites this paper
• Ofatumumab and high-dose methylprednisolone for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia

  2014cites this paper
• Target Therapy in Hematological Malignances: New Monoclonal Antibodies

  2014cites this paper
• Molecular Pathology of Chronic Lymphocytic Leukemia and Relevance to Novel Therapies

  2014cites this paper
• Ofatumumab (Arzerra®): a Next‐Generation Human Therapeutic CD20 Antibody with Potent Complement‐Dependent Cytotoxicity

  2014cites this paper
• Targeting antiapoptotic and proapoptotic proteins for novel chronic lymphocytic leukemia therapeutics

  2014cites this paper
• Targeting Susceptible Signaling Pathways in Chronic Lymphocytic Leukemia

  2014cites this paper
• Successful Treatment of Refractory Guillain-Barré Syndrome with Alemtuzumab in a Patient with Chronic Lymphocytic Leukemia

  2014cites this paper
• FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia

  2014influential citation
• The differences in thermal profiles between normal and leukemic cells exposed to anticancer drug evaluated by differential scanning calorimetry

  2014cites this paper
• A Breakthrough Therapy in Relapsed Chronic Lymphocytic Leukemia: the Combination of Idelalisib and Rituximab

  2014cites this paper
• Apoptosis inducers in chronic lymphocytic leukemia

  2013cites this paper
• Treatment challenges in the management of relapsed or refractory non-Hodgkin’s lymphoma – novel and emerging therapies

  2013cites this paper
• Chronic lymphocytic leukemia: molecular heterogeneity revealed by high-throughput genomics

  2013cites this paper
• A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine

  2013cites this paper
• Tumor Protein p53 (TP53) Testing and Li-Fraumeni Syndrome

  2013cites this paper
• Characterising CD31/CD38 signalling in primary chronic lymphocytic leukaemia cells

  2013cites this paper
• Identification and validation of potential targets for the diagnosis and therapy of chronic lymphocytic leukaemia

  2013cites this paper
• Safety and efficacy of ofatumumab in patients with fludarabine and alemtuzumab refractory chronic lymphocytic leukaemia

  2012cites this paper
• A case of chronic lymphocytic leukemia with massive ascites

  2012cites this paper